aptaTargets — Series A · €5M

aptaTargets is developing ApTOLL, an aptamer drug for acute ischaemic stroke. It closed a €5M second financing round, of which €2.3M is equity from Inveready and CDTI (Innvierte) and about €2.7M is public funding and grants mobilised over 2020–2022; the money funds clinical trials. The round is unlettered and classed here as Series A as the company's second round.